Next Article in Journal
Prediction of Pharmacokinetic Parameters Using a Genetic Algorithm Combined with an Artificial Neural Network for a Series of Alkaloid Drugs
Previous Article in Journal
Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl- 1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors

by
Marc LINDNER
1,
Wolfgang SIPPL
1 and
Awwad A. RADWAN
2,3,*
1
Department of Pharmaceutical Chemistry, Martin-Luther-Universität Halle-Wittenberg, 06120 Halle, Germany
2
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut-71527, Egypt
3
Pharmaceutical Technology and Manufacturing Center, College of Pharmacy, King Saud University Al Ryiadh, Kingdom of Saudi Arabia, P. O. Box 2457, Riyadh, 11451, Kingdom of Saudi Arabia
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2010, 78(2), 195-214; https://doi.org/10.3797/scipharm.0912-19
Submission received: 20 December 2009 / Accepted: 18 March 2010 / Published: 19 March 2010

Abstract

A set of 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid derivatives (16–32) showing anti-inflammatory activity was analyzed using a threedimensional qualitative structure-selectivity relationship (3D QSSR) method. The CatalystHipHop approach was used to generate a pharmacophore model for cyclooxygenase-2 (COX-2) inhibitors based on a training set of 15 active inhibitors (1–15). The degree of fitting of the test set compounds (16–32) to the generated hypothetical model revealed a qualitative measure of the more or less selective COX-2 inhibition of these compounds. The results indicate that most derivatives (16, 18, 20–25, and 30–32) are able to effectively satisfy the proposed pharmacophore geometry using energy accessible conformers (Econf < 20 kcal/mol). In addition, the triazole derivatives (16–32) were docked into COX-1 and COX-2 X-ray structures, using the program GOLD. Based on the docking results it is suggested that several of these novel triazole derivatives are active COX inhibitors with a significant preference for COX-2. In principle, this work presents an interesting, comprehensive approach to theoretically predict the mode of action of compounds that showed anti-inflammatory activity in an in vivo model.
Keywords: Catalyst; COX; GOLD; Docking; Pharmacophore Catalyst; COX; GOLD; Docking; Pharmacophore

Share and Cite

MDPI and ACS Style

LINDNER, M.; SIPPL, W.; RADWAN, A.A. Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl- 1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors. Sci. Pharm. 2010, 78, 195-214. https://doi.org/10.3797/scipharm.0912-19

AMA Style

LINDNER M, SIPPL W, RADWAN AA. Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl- 1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors. Scientia Pharmaceutica. 2010; 78(2):195-214. https://doi.org/10.3797/scipharm.0912-19

Chicago/Turabian Style

LINDNER, Marc, Wolfgang SIPPL, and Awwad A. RADWAN. 2010. "Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl- 1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors" Scientia Pharmaceutica 78, no. 2: 195-214. https://doi.org/10.3797/scipharm.0912-19

APA Style

LINDNER, M., SIPPL, W., & RADWAN, A. A. (2010). Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl- 1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors. Scientia Pharmaceutica, 78(2), 195-214. https://doi.org/10.3797/scipharm.0912-19

Article Metrics

Back to TopTop